Neutrolis develops precision therapies that target Neutrophil Extracellular Traps (NETs) to mitigate tissue damage associated with autoimmune and inflammatory diseases. By utilizing their exDNASE™ platform, the company creates engineered molecules that disassemble harmful NETs, addressing the underlying causes of immune-mediated disorders.
Funding
$44.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neutrophil Extracellular Traps (NETs), formed by overactive neutrophils, cause tissue damage and contribute to the pathology of autoimmune and inflammatory diseases. Current treatments often address symptoms without targeting the underlying NETs that drive these disorders. Existing methods for studying neutrophil biology have limitations, hindering the development of targeted therapies.
Solution
Neutrolis is developing precision therapies that target and neutralize NETs to mitigate tissue damage associated with autoimmune and inflammatory diseases. The company's exDNASE™ platform engineers molecules designed to disassemble harmful NETs, addressing the root cause of immune-mediated disorders. By combining these engineered molecules with NET biomarker technology, Neutrolis aims to transform disease treatment through a precision medicine approach. This strategy allows for the development of therapies that specifically target the underlying causes of diseases like lupus, rather than merely treating the symptoms.
Target Audience
The primary target audience includes patients suffering from autoimmune and inflammatory diseases, as well as clinicians and researchers focused on developing and implementing precision therapies for these conditions.
Features
- exDNASE™ platform for designing molecules that disassemble NETs
- NET biomarker technology for precision medicine applications
- Engineered molecules specifically designed to neutralize NETs
- Focus on autoimmune, inflammatory, thrombosis & complement, tumor metastasis, and mechanical occlusions
- Translational breakthroughs leading to an enhanced understanding of NETosis and its clearance pathways